Randomized trial of fluconazole versus low‐dose amphotericin B in prophylaxis against fungal infections in patients undergoing hematopoietic stem cell transplantation
- 22 November 2002
- journal article
- clinical trial
- Published by Wiley in American Journal of Hematology
- Vol. 71 (4) , 260-267
- https://doi.org/10.1002/ajh.10234
Abstract
Over the past decade, invasive fungal infections have become an increasingly important problem in patients undergoing hematopoietic stem cell transplantation (HSCT). The optimal approach for prophylactic antifungal therapy has yet to be determined. To resolve this issue, we performed a prospective randomized study to compare the efficacy of fluconazole (FL) versus low‐dose amphotericin B (AmB) in preventing fungal infections during the first 100 days after HSCT. Patients undergoing allogenic or autologous HSCT were randomized to receive fluconazole 200 mg/day PO or amphotericin B 0.2 mg/kg/day IV beginning 1 day prior to commencement of conditioning regimen and continuing until engraftment, drug‐associated toxicity was suspected, or systemic fungal infection was suspected or proven. High‐dose amphotericin B (0.5–1.0 mg/kg/day) was started for patients with suspected or proven fungal infections. From January 1993 to December 1998, a total of 186 patients were enrolled into the trial, with 100 receiving FL and 86 receiving AmB. Eighty (43%) patients were removed from prophylaxis for persistent fever despite broad‐spectrum antibacterial therapy or suspected fungal infections (FL 46 vs. AmB 34, P > 0.05). The incidence of proven fungal infections (FL 12% vs. AmB 12.8%), suspected fungal infections (FL 4% vs. AmB 2.3%), superficial fungal infections (FL 1% vs. AmB 4.6%) did not show any significant difference. The survival at 100 days post transplant was similar between the 2 groups (FL 78% vs. AmB 70%, P = 0.254). Death attributable to fungal infections was similar in both groups (6% vs. 7%, P > 0.05). We conclude that fluconazole is as effective as low‐dose amphotericin B in prophylaxis against fungal infections in patients undergoing hematopoietic cell transplantation. Am. J. Hematol. 71:260–267, 2002.Keywords
This publication has 26 references indexed in Scilit:
- Presalvage prostate‐specific antigen (PSA) and PSA doubling time as predictors of biochemical failure of salvage cryotherapy in patients with locally recurrent prostate cancer after radiotherapyCancer, 2006
- Oral antifungals as prophylaxis in haematological malignancyBlood Reviews, 2001
- A randomized controlled trial of itraconazole versus fluconazole for the prevention of fungal infections in patients with haematological malignanciesBritish Journal of Haematology, 1999
- Itraconazole Oral Solution as Prophylaxis for Fungal Infections in Neutropenic Patients with Hematologic Malignancies: A Randomized, Placebo‐Controlled, Double‐Blind, Multicenter TrialClinical Infectious Diseases, 1999
- Randomized Placebo‐Controlled Trial of Fluconazole Prophylaxis for Neutropenic Cancer Patients: Benefit Based on Purpose and Intensity of Cytotoxic TherapyClinical Infectious Diseases, 1999
- An autopsy study of systemic fungal infections in patients with hematologic malignanciesEuropean Journal of Clinical Microbiology & Infectious Diseases, 1995
- Efficacy and Safety of Fluconazole Prophylaxis for Fungal Infections after Marrow Transplantation--A Prospective, Randomized, Double-Blind StudyThe Journal of Infectious Diseases, 1995
- Prophylactic Intravenous Amphotericin B in Neutropenic Autologous Bone Marrow Transplant RecipientsThe Journal of Infectious Diseases, 1992
- A Controlled Trial of Fluconazole to Prevent Fungal Infections in Patients Undergoing Bone Marrow TransplantationNew England Journal of Medicine, 1992
- Efficacy of Fluconazole in Experimental Invasive AspergillosisClinical Infectious Diseases, 1990